Tocilizumab: Therapy and safety management - 18/06/10
, Pascal Claudepierre 2, Arnaud Constantin 3, Michel de Bandt 4, Bruno Fautrel 5, Laure Gossec 6, Jacques-Eric Gottenberg 7, Philippe Goupille 8, Séverine Guillaume 9, Eric Hachulla 10, Charles Masson 11, Jacques Morel 12, Xavier Puéchal 13, Alain Saraux 14, Thierry Schaeverbeke 15, Daniel Wendling 16, Eric Bruckert 17, Stanislas Pol 18, Xavier Mariette 19, Jean Sibilia 20
Corresponding author. Tel.: +33 4 91 38 34 62; fax: +33 4 91 38 38 87.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 98 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
:
To develop fact sheets about tocilizumab, in order to assist physicians in the management of patients with inflammatory joint disease.
Methods |
:
1. | selection by a committee of rheumatology experts of the main topics of interest for which fact sheets were desirable; |
2. | identification and review of publications relevant to each topic; |
3. | development of fact sheets based on three levels of evidence: evidencebased medicine, official recommendations, and expert opinion. The 20 experts were rheumatologists and invited specialists in other fields, and they had extensive experience with the management of RA. They were members of the CRI (Club Rhumatismes et Inflammation), a section of the Société Francaise de Rhumatologie. Each fact sheet was revised by several experts and the overall process was coordinated by three experts. |
Results |
:
Several topics of major interest were selected: contraindications of tocilizumab; the management of adverse effects and concomitant diseases that may develop during tocilizumab therapy; and the management of everyday situations such as pregnancy, surgery, and immunizations. After a review of the literature and discussions among experts, a consensus was developed about the content of the fact sheets presented here. These fact sheets focus on several points:
1. | in RA, initiation and monitoring of tocilizumab therapy, management of patients with specific past histories, and specific clinical situations such as pregnancy; |
2. | diseases other than RA, such as juvenile idiopathic arthritis; |
3. | models of letters for informing the rheumatologist and general practitioner; |
4. | and patient information. |
Conclusion |
:
These tocilizumab fact sheets built on evidence-based medicine and expert opinion will serve as a practical tool for assisting physicians who manage patients on tocilizumab therapy. They will be available continuously at www.cri-net.com/ and updated at appropriate intervals.
Le texte complet de cet article est disponible en PDF.Plan
Vol 77 - N° S1
P. S3-S100 - juin 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?